Yip's Chemical Holdings: Sino Biopharmaceutical will pay the company a one-time profit share of 80 million RMB.

Shouyao Holdings Announcement: Recently, based on strategic considerations from all parties, and after friendly negotiations, all parties have unanimously agreed to adjust the cooperation revenue sharing, amount, intellectual property rights ownership, and other models in the aforementioned "Technology Development Contract". They have also signed a supplementary agreement on the "Technology Development Contract" and a knowledge transfer agreement for the innovative JAK2 inhibitor anticancer drug collaboration under the "Technology Development Contract". After this adjustment, in addition to the previously agreed milestone income of RMB 3 million for the JAK2 inhibitor obtained by the China National Medical Products Administration, Zhengda Tianqing will also pay the company a one-time profit sharing of RMB 80 million in two installments. Once Zhengda Tianqing has paid the aforementioned RMB 83 million, it will be considered that Zhengda Tianqing and Runzhong Pharmaceutical have fulfilled their payment obligations under the original agreement.